The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

The US Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones. The new app works with the FreeStyle Libre 2 with optional glucose alarms, which ...

This morning Abbott revealed that its much anticipated integrated continuous glucose monitoring system the FreeStyle Libre 2 is now FDA cleared for adults and kids over the age of 4 with diabetes. The ...

Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

The FreeStyle Libre GCM can monitor your glucose levels without needing a blood sample. Here’s what you should know about how to use it, where you can get it, and how it compares to other glucose ...

Patients are being warned to stop using some glucose monitors made by Abbott Diabetes Care after the company found malfunctioning sensors may be linked to hundreds of adverse events and several deaths ...

Manage your diabetes with confidence¹ using the FreeStyle Libre 2 system and Gro Health. The FreeStyle Libre 2 system can help improve glycaemic control in type 2 diabetes¹,² along with using Gro ...

The U.S. FDA finally granted Abbott Laboratories' Freestyle Libre 2 clearance as an integrated continuous glucose monitor (iCGM) for adults and children age 4 and older with diabetes. Abbott received ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...